Hemostemix Inc. (CVE:HEM – Get Free Report) shares traded down 22.9% on Friday . The stock traded as low as C$0.18 and last traded at C$0.19. 504,239 shares were traded during mid-day trading, a decline of 5% from the average session volume of 530,580 shares. The stock had previously closed at C$0.24.
Hemostemix Trading Down 22.9 %
The company has a debt-to-equity ratio of -55.07, a quick ratio of 0.48 and a current ratio of 0.04. The business’s 50 day moving average price is C$0.19 and its 200-day moving average price is C$0.11. The firm has a market cap of C$26.96 million, a price-to-earnings ratio of -5.39 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
- Profitably Trade Stocks at 52-Week Highs
- Cisco Roars Back: Is the Tech Giant Reborn?
- What Are Treasury Bonds?
- Albemarle’s Earnings Are In—Is the Stock a Buy Now?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
